0
Orphan Designations
2
FDA Approvals
Latest: Tecartus (2020)
0
Active Trials
4
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Kite Pharma (Gilead) is a company with 0 orphan drug designations across 4 rare diseases, including 2 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| B-cell acute lymphoblastic leukemia | Tecartus | Des.TrialAppr. |
| diffuse large B-cell lymphoma | Yescarta | Des.TrialAppr. |
| follicular lymphoma | Yescarta | Des.TrialAppr. |
| mantle cell lymphoma | Tecartus | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
22
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
22
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio